NeurologyLive® Mind Moments®

NeurologyLive

About

Mind Moments®, a podcast from NeurologyLive® (https://www.neurologylive.com/) , brings you exclusive interviews with experts in neurologic disorders.

Listen in to hear the latest clinical and research updates from major medical conferences, as well as insights on the management of complex disorders, including epilepsy, migraine, Alzheimer disease, stroke, multiple sclerosis, Parkinson disease, and more.

For more expert insight into neurology, visit NeurologyLive.com (https://www.neurologylive.com/) .

Available on

Community

122 episodes

111: Reviewing ACTRIMS 2024

* Welcome to the ® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, Daniel Ontaneda, MD, an associate professor of neurology at the Cleveland Clinic Lerner College of Medicine, sat down to discuss the recently concluded Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum. Ontaneda, program committee vice-chair of the meeting, provided insight on a number of notable sessions and discussions that highlighted the recent advances in the MS field. In addition, he talked about the need to innovate clinical trials, ways to tackle progressive MS, and whether drug trials are truly assessing patients at the right time points. Furthermore, he discussed multi-stage trials, the potential role of Bruton tyrosine kinase (BTK) inhibitors, and how this year's meeting differs from previous ones.  LOOKING FOR MORE MULTIPLE SCLEROSIS DISCUSSION? CHECK OUT THE ® MULTIPLE SCLEROSIS CLINICAL FOCUS PAGE https://www.neurologylive.com/clinical/ms. Episode Breakdown: __ 1:05 – Overviewing sessions from ACTRIMS Forum 13:10 – Innovating clinical trial design 16:15 – 2023 ACTRIMS vs 2024 ACTRIMS 20:20 – Neurology News Minute 23:30 – Testing combination approaches for progressive MS 26:45 – The impact of timing therapeutic interventions  __ * THIS EPISODE IS BROUGHT TO YOU BY , A STREAMING CHANNEL FROM MJH LIFE SCIENCES®. CHECK OUT NEW CONTENT AND SHOWS EVERY DAY, ONLY AT MEDICALWORLDNEWS.COM http://medicalworldnews.com/. The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: __ FDA ADCOMM TO REVIEW INVESTIGATIONAL ALZHEIMER AGENT DONANEMAB AND PHASE 3 RESULTS https://www.neurologylive.com/view/fda-adcomm-review-investigational-alzheimer-agent-donanemab-phase-3-results AMYLYX MULLS OVER PULLING AMX0035 FOLLOWING DISAPPOINTING PHASE 3 PHOENIX FINDINGS https://www.neurologylive.com/view/amylyx-mulls-over-pulling-amx0035-following-disappointing-phase-3-phoenix-findings FDA ISSUES COMPLETE RESPONSE LETTER FOR LONG-ACTING FORM OF GLATIRAMER ACETATE FOR RELAPSING MULTIPLE SCLEROSIS https://www.neurologylive.com/view/fda-issues-crl-long-acting-form-glatiramer-acetate-relapsing-ms __ * Thanks for listening to the ® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com http://neurologylive.com/.

30m
Mar 22
110: Differential Diagnosis of Sleep Disorders and Hypersomnias

* Welcome to the ® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, Alcibiades Rodriguez, MD, medical director of the Comprehensive Epilepsy Center—Sleep Center at NYU Langone discussed several sleep-related topics, including the diagnosis of rare sleep disorders and hypersomnias. He spoke on the treatment of obstructive sleep apnea, the importance of adherence to medication, and the ways clinicians can help patients stick to their treatment regimen. Furthermore, he talked about the conversations between patients and clinicians to ensure an accurate diagnosis, as well as the emerging research in the sleep disorder field over the coming years. LOOKING FOR MORE SLEEP DISORDERS DISCUSSION? CHECK OUT THE ® SLEEP DISORDERS CLINICAL FOCUS PAGE https://www.neurologylive.com/clinical/sleep-medicine. Episode Breakdown: __ 1:40 – Conversations needed to differentiate diagnoses 4:30 – Appearance of sleep disorders and overlap 6:50 – Complications with untreated sleep apnea 8:25 – Neurology News Minute 10:55 – Ways to improve adherence to medication 13:50 – Emerging research in the field __ * THIS EPISODE IS BROUGHT TO YOU BY , A STREAMING CHANNEL FROM MJH LIFE SCIENCES®. CHECK OUT NEW CONTENT AND SHOWS EVERY DAY, ONLY AT MEDICALWORLDNEWS.COM http://medicalworldnews.com/. The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: __ GLATIRAMER ACETATE DEPOT DEMONSTRATES SUSTAINED LONGTERM SAFETY PROFILE AS POTENTIAL MS THERAPY https://www.neurologylive.com/view/glatiramer-acetate-depot-demonstrates-sustained-longterm-safety-potential-ms-therapy PHASE 3 DAYBREAK TRIAL HIGHLIGHTS LONG-TERM EFFICACY OF OZANIMOD FOR RELAPSING MULTIPLE SCLEROSIS https://www.neurologylive.com/view/phase-3-daybreak-trial-highlights-longterm-efficacy-ozanimod-relapsing-ms SRP-9001 IMPROVES DUCHENNE MUSCULAR DYSTROPHY DISEASE TRAJECTORY DESPITE FAILING TO MEET PRIMARY END POINT IN PHASE 3 EMBARK TRIAL https://www.neurologylive.com/view/srp-9001-improves-duchenne-muscular-dystrophy-disease-trajectory-despite-failing-meet-primary-end-point-phase-3-embark-trial __ * Thanks for listening to the ® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com http://neurologylive.com/.

19m
Mar 08
109: AB126, Exosomes, and Cerebroprotection for Stroke

* Welcome to the ® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, Stephen From, chief executive officer of Aruna Bio, sat down to discuss the company's investigational exosome candidate AB126 and its upcoming phase 1b/2a trial in patients with ischemic stroke. He discussed the mechanism of action of the therapy, the advantages of its anti-inflammatory and neuroprotective properties, and how it will be used with other stroke treatments. Furthermore, he gave insight on the complexities with conducting stroke trials and improving neurodegeneration in poststroke patients.  LOOKING FOR MORE STROKE DISCUSSION? CHECK OUT THE ® STROKE CLINICAL FOCUS PAGE https://www.neurologylive.com/clinical/stroke. Episode Breakdown: __ 1:00 – Overviewing phase 1b/2a trial 7:05 – Mechanism of action of AB126 11:15 – Neurology News Minute 13:45 – Role of AB126 in stroke treatment landscape 17:50 – Challenges with repairing neurodegeneration in stroke __ * THIS EPISODE IS BROUGHT TO YOU BY , A STREAMING CHANNEL FROM MJH LIFE SCIENCES®. CHECK OUT NEW CONTENT AND SHOWS EVERY DAY, ONLY AT MEDICALWORLDNEWS.COM http://medicalworldnews.com/. The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: __ EUROPEAN COMMISSION APPROVES OMAVELOXOLONE AS FIRST THERAPY FOR FRIEDREICH ATAXIA https://www.neurologylive.com/view/european-commission-approves-omaveloxolone-first-therapy-friedreich-ataxia AVP-786 FALLS SHORT IN PHASE 3 STUDY OF ALZHEIMER DISEASE AGITATION https://www.neurologylive.com/view/avp-786-falls-short-phase-3-study-alzheimer-disease-agitation FDA GRANTS PRIORITY REVIEW TO EFFICACY SUPPLEMENT FOR SAREPTA THERAPEUTICS’ SRP-9001 INDICATION EXPANSION https://www.neurologylive.com/view/fda-grants-priority-review-efficacy-supplement-sarepta-therapeutics-srp-9001-indication-expansion __ * Thanks for listening to the ® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com http://neurologylive.com/.

22m
Feb 23
108: Advancing the Genetic Pool of Parkinson Disease

* Welcome to the ® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, Igancio Mata, PhD, sat down to discuss a recently published meta-analysis on the genetic backgrounds of Parkinson disease beyond traditional European populations. Mata, an associate professor in the Genomic Medicine Institute at Cleveland Clinic, provided insight on the newly identified novel loci and how the data adds to previous genome-wide association studies. In addition, he gave thoughts on the possibility of gene therapy and some of the barriers that come with it, as well as the feasibility of incorporating genetic checkpoints into clinical trial inclusion criteria.  LOOKING FOR MORE MOVEMENT DISORDER DISCUSSION? CHECK OUT THE ® MOVEMENT DISORDER CLINICAL FOCUS PAGE https://www.neurologylive.com/clinical/movement-disorders. Episode Breakdown: __ 1:10 – Meta-analysis overview 3:20 – Significance of results, how they add to the literature 6:50 – Feasibility of incorporating genetic screening into clinical trials 8:40 – Neurology News Minute 11:15 – Realistic expectations and potential with gene therapy 15:45 – Next steps in advancing this research __ * THIS EPISODE IS BROUGHT TO YOU BY , A STREAMING CHANNEL FROM MJH LIFE SCIENCES®. CHECK OUT NEW CONTENT AND SHOWS EVERY DAY, ONLY AT MEDICALWORLDNEWS.COM http://medicalworldnews.com/. The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: __ BIOGEN WALKS AWAY FROM ADUCANUMAB TO PRIORITIZE LECANEMAB AND ALZHEIMER DISEASE PIPELINE https://www.neurologylive.com/view/biogen-walks-away-from-aducanumab-prioritize-lecanemab-alzheimer-disease-pipeline UPDATED GUIDELINES PUBLISHED TO IMPROVE CARE IN SPECIALIZED EPILEPSY CENTERS https://www.neurologylive.com/view/updated-guidelines-published-improve-care-specialized-epilepsy-centers FDA CLEARS IND FOR GENE THERAPY CANDIDATE ETX101 IN DRAVET SYNDROME https://www.neurologylive.com/view/fda-clears-ind-gene-therapy-candidate-etx101-dravet-syndrome __ * Thanks for listening to the ® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com http://neurologylive.com/.

21m
Feb 09
107: Revealing Mechanisms of Sudden Unexplained Death in Toddlers

* Welcome to the ® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, Orrin Devinsky, MD, director of the NYU Langone Comprehensive Epilepsy Center, provided commentary on a recently published study assessing video evidence of sudden unexplained deaths in toddlers. Devinsky, who also serves as a professor of neurology, discussed the importance behind crib cams, the moments captured prior to the deaths assessed, and the involvement of seizure activity even with no prior history. In addition, he spoke on the abnormal sounds and movements of these children, the ways to advance SUDC research, and the next steps in understanding and relaying the data.  LOOKING FOR MORE EPILEPSY DISCUSSION? CHECK OUT THE ® EPILEPSY CLINICAL FOCUS PAGE https://www.neurologylive.com/clinical/epilepsy. Episode Breakdown: __ 1:10 – Reasons behind studying sudden death in toddlers 3:55 – Notable takeaways from trial results 8:15 – Advancing ways to research SUDC/SUDEP 9:40 – Neurology News Minute 12:05 – Realistic ways to lower convulsive activity prior to sleep  15:05 – What abnormal movements/noises can ellucidate 15:55 – Ways to expand the research further __ * THIS EPISODE IS BROUGHT TO YOU BY , A STREAMING CHANNEL FROM MJH LIFE SCIENCES®. CHECK OUT NEW CONTENT AND SHOWS EVERY DAY, ONLY AT MEDICALWORLDNEWS.COM http://medicalworldnews.com/. The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: __ FDA APPROVES TAKEDA’S IMMUNE GLOBULIN INFUSION, HYQVIA, FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY https://www.neurologylive.com/view/fda-approves-takeda-hyqvia-chronic-inflammatory-demyelinating-polyneuropathy FDA ISSUES COMPLETE RESPONSE LETTER FOR SATSUMA’S DHE NASAL POWDER STS101 TO TREAT ACUTE MIGRAINE https://www.neurologylive.com/view/fda-issues-crl-satsuma-dhe-nasal-powder-sts101-acute-migraine ALS AGENT PRIMEC TO ADVANCE TO PHASE 3 STUDY AFTER POSITIVE PARADIGM TRIAL DATA https://www.neurologylive.com/view/als-agent-primec-advance-phase-3-study-positive-paradigm-trial-data __ * Thanks for listening to the ® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com http://neurologylive.com/.

18m
Jan 26
106: Potential Role of Stathmin-2 in Amyotrophic Lateral Sclerosis

* Welcome to the ® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, Cathleen Lutz, PhD, vice president of the Rare Disease Translational Center at the Jackson Laboratory, provided comment on a recently published study which unveiled that stathmin-2 loss leads to neurofilament-dependent axonal collapse in patients with amyotrophic lateral sclerosis (ALS). Lutz offered insight on the role stathmin-2 may have in this disease, the questions that still remain, and whether restoration of stathmin-2 may be an attractive therapeutic approach. Furthermore, she spoke on the potential of this protein as a disease-modifying biomarker and whether it may be incorporated in trials in the near future.  LOOKING FOR MORE NEUROMUSCULAR DISCUSSION? CHECK OUT THE ® NEUROMUSCULAR CLINICAL FOCUS PAGE https://www.neurologylive.com/clinical/neuromuscular. Episode Breakdown: __ 1:15 – Idea behind studying stathmin-2 2:45 – Overviewing study results 7:05 – Next steps in extending this research 8:40 – Neurology News Minute 11:30 – Stathmin-2's connection with neurofilament light 12:55 – Potential of stathmin-2 as ALS-specific biomarker 14:45 – Future use of stathmin-2 in clinical trials 15:30 – Closing thoughts __ * THIS EPISODE IS BROUGHT TO YOU BY , A STREAMING CHANNEL FROM MJH LIFE SCIENCES®. CHECK OUT NEW CONTENT AND SHOWS EVERY DAY, ONLY AT MEDICALWORLDNEWS.COM http://medicalworldnews.com/. The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: __ FDA CLEARS PHASE 2 KYSA-7 STUDY OF CAR T-CELL THERAPY IN REFRACTORY PROGRESSIVE MULTIPLE SCLEROSIS https://www.neurologylive.com/view/fda-clears-phase-2-kysa-7-study-car-t-cell-therapy-refractory-progressive-multiple-sclerosis DYNE REPORTS POSITIVE PHASE 1/2 DATA FOR DUCHENNE AGENT DYNE-251 https://www.neurologylive.com/view/dyne-reports-positive-phase-1-2-data-duchenne-agent-dyne-251 PARKINSON GENE THERAPY AB-1005 MEETS PRIMARY END POINT IN PHASE 1B TRIAL https://www.neurologylive.com/view/parkinson-gene-therapy-ab-1005-meets-primary-end-point-phase-1b-trial VISIONARY-MS TRIAL REPORTS CNM-AU8 IMPROVES VISION AND COGNITION IN MULTIPLE SCLEROSIS https://www.neurologylive.com/view/visionary-ms-trial-reports-cnm-au8-improves-vision-cognition-multiple-sclerosis __ * Thanks for listening to the ® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com http://neurologylive.com/.

18m
Jan 12
105: Recapping Conversations in Neurology From 2023

* Welcome to the ® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we comprised some of the most interesting conversations from Mind Moments podcast episodes in 2023, highlighting research in neurology that moves the field forward. The NeurologyLive team included several reaction episodes to FDA approved medicines, providing clinicians an overview of what they can expect from these new therapies and how they will be used in clinic going forward. Those included in this week's episode, in order of appearance, are: __ SHARON COHEN, MD, FRCPC, behavioral neurologist and medical director of the Toronto Memory Program at the University of Toronto, and a trial investigator for Clarity AD, the phase 3 trial of lecanemab. __ Check out the full episode here: https://www.neurologylive.com/view/special-episode-lecanemab-approved-for-alzheimer-disease __ ROBERT A. HAUSER, MD, MBA, director of the Parkinson’s and Movement Disorders Center at the University of South Florida.__ Check out the full episode here: https://www.neurologylive.com/view/episode-81-widening-therapeutic-window-parkinson-disease __ ALBERTO ESPAY, MD, PHD, the division director and Research Endowed Chair of the James J. and Joan A. Gardner Family Center for Parkinson’s Disease and Movement Disorders, and a professor of clinical neurology and rehabilitation medicine at the University of Cincinnati.__ Check out the full episode here: https://www.neurologylive.com/view/episode-94-discussion-leqembi-lecanemab-approval-alzheimer-disease __ CAROLINA FERREIRA ATUESTA, MD, MSC, a scientific researcher and clinical data manager at the Icahn School of Medicine at Mount Sinai.__ Check out the full episode here: https://www.neurologylive.com/view/episode-82-managing-seizures-after-ischemic-stroke __ NATALIE GOEDEKER, CPNP, a nurse practitioner in neurology in the Neuromuscular Division at Washington University in St Louis.__ Check out the full episode here: https://www.neurologylive.com/view/special-episode-tofersen-approved-sod1-als __ __ * https://www.neurologylive.com/podcasts Episode Breakdown: __ 1:20 – Cohen on the safety of lecanemab, including the 3 patient deaths reported in the supportive clinical trial program.  6:25 – Hauser on the clinical advantages of IPX203, a potential new carbidopa/levodopa formulation for patients with Parkinson disease.  9:20 – Espay on tempering expectations of lecanemab and other antiamyloid therapies in the treatment of Alzheimer disease. 13:20 – Atuesta on the lack of standardized methods for monitoring patients with poststroke seizures, including elders. 17:00 – Goedeker on the approval of gene therapy SRP-9001 for patients with Duchenne muscular dystrophy, the integration process, and safety considerations clinicians should be aware of. __ * THIS EPISODE IS BROUGHT TO YOU BY , A STREAMING CHANNEL FROM MJH LIFE SCIENCES®. CHECK OUT NEW CONTENT AND SHOWS EVERY DAY, ONLY AT MEDICALWORLDNEWS.COM http://medicalworldnews.com/. Thanks for listening to the ® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com http://neurologylive.com/.

21m
Dec 29, 2023
104: Effects of Once-Nightly Sodium Oxybate on Narcolepsy Type 1 and 2

* Welcome to the ® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, Jennifer Gudeman, senior vice president of medical and clinical affairs for Avadel Pharmaceuticals, sat down to discuss a recently published post-hoc analysis of the phase 3 REST-ON trial of once-nightly sodium oxybate (Lumryz). In the conversation, Gudeman talked about the impact of the drug on both narcolepsy types 1 and 2, the differences between these 2 subtypes, and the ways clinical trials of narcolepsy agents continue to evolve. Furthermore, she spoke on some of the unmet needs for this patient population, including lingering brain fog and overcoming negative stigmas.  LOOKING FOR MORE SLEEP DISORDERS DISCUSSION? CHECK OUT THE ® NARCOLEPSY CLINICAL FOCUS PAGE https://www.neurologylive.com/disease-spotlight/disease-spotlight-narcolepsy. Episode Breakdown: __ 1:10 – Overview of post-hoc analysis of REST-ON 3:15 – Differences in type 1 and 2 narcolepsy 5:50 – Neurology News Minute 8:15 – Expanding treatment profile of once-nightly sodium oxybate 10:55 – Lingering unmet needs of patients with narcolepsy 11:20 – Realistic timeline of gene therapies for epilepsy 14:00 – Future of narcolepsy research, drug development trials __ * THIS EPISODE IS BROUGHT TO YOU BY , A STREAMING CHANNEL FROM MJH LIFE SCIENCES®. CHECK OUT NEW CONTENT AND SHOWS EVERY DAY, ONLY AT MEDICALWORLDNEWS.COM http://medicalworldnews.com/. The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: __ FDA PLACES CLINICAL HOLD ON ROCHE’S BTK INHIBITOR FENEBRUTINIB FOR MULTIPLE SCLEROSIS https://www.neurologylive.com/view/fda-places-clinical-hold-roche-btk-inhibitor-fenebrutinib-multiple-sclerosis ALS CANDIDATE PRIMEC MEETS PRIMARY SAFETY AND SECONDARY END POINTS IN PHASE 2B PARADIGM STUDY https://www.neurologylive.com/view/als-candidate-primec-meets-primary-safety-secondary-endpoints-phase-2b-paradigm-study FDA CLEARS NEUROONE’S ONERF ABLATION SYSTEM FOR NEUROSURGERICAL PROCEDURES https://www.neurologylive.com/view/fda-clears-neuroone-onerf-ablation-system-neurosurgerical-procedures __ * Thanks for listening to the ® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com http://neurologylive.com/.

17m
Dec 15, 2023
103: Advancing Epilepsy Care and Seizure Localization in Pediatrics

* Welcome to the ® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, William Gallentine, DO, interim chief of pediatric neurology at Stanford Medicine Children’s Health, who discussed several topics related to the advances in pediatric epilepsy, epilepsy surgery, and seizure localization. Gallentine, who also serves as a clinical professor, provided insight on the screening process and eligibility criteria for epilepsy surgery, as well as the importance of lifestyle modifications when treating epilepsy. Furthermore, he touched upon the genetic background of certain epileptic disorders and when the clinical community can expect gene therapies. LOOKING FOR MORE EPILEPSY DISCUSSION? CHECK OUT THE ® EPILEPSY CLINICAL FOCUS PAGE https://www.neurologylive.com/clinical/epilepsy. Episode Breakdown: __ 1:10 – State of pediatric epilepsy 2:15 – Screening potential candidates for epilepsy surgery 5:00 – Advances in seizure localization 7:15 – Neurology News Minute 9:25 – Balance of nonpharmacological approaches 11:20 – Realistic timeline of gene therapies for epilepsy 13:15 – Future plans for research, current unmet needs __ * THIS EPISODE IS BROUGHT TO YOU BY , A STREAMING CHANNEL FROM MJH LIFE SCIENCES®. CHECK OUT NEW CONTENT AND SHOWS EVERY DAY, ONLY AT MEDICALWORLDNEWS.COM http://medicalworldnews.com/. The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: __ FDA CLEARS AI-POWERED BRAIN MRI SOFTWARE PIXYL.NEURO https://www.neurologylive.com/view/fda-clears-ai-powered-brain-mri-software-pixyl-neuro FDA GRANTS MEETING WITH BRAINSTORM CELL THERAPEUTICS ON ALS THERAPY NUROWN https://www.neurologylive.com/view/fda-grants-meeting-brainstorm-cell-therapeutics-als-therapy-nurown FDA WARNS OF SERIOUS ADVERSE EFFECTS FOR USING LEVETIRACETAM AND CLOBAZAM IN EPILEPSY https://www.neurologylive.com/view/fda-warns-serious-adverse-effects-using-levetiracetam-clobazam-epilepsy __ * Thanks for listening to the ® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com http://neurologylive.com/.

17m
Dec 01, 2023
102: Potential of Gamma Sensory Stimulation in Alzheimer Disease

* Welcome to the ® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, Brett Vaughan, chief executive officer of Cognito Therapeutics, provided insight on the mechanism of action behind the company's gamma sensory stimulation as a potential therapy for patients with Alzheimer disease. He spoke on the positive phase 2 OVERTURE study presented at the 2023 Clinical Trials on Alzheimer's Disease (CTAD) conference, including the notable takeaways from the trial and the safety profile observed. In addition, he commented on how this approach can be used with newer therapies and what the company is looking to achieve in a phase 3 trial. LOOKING FOR MORE ALZHEIMER DISEASE/DEMENTIA DISCUSSION? CHECK OUT THE ® ALZHEIMER DISEASE/DEMENTIA CLINICAL FOCUS PAGE https://www.neurologylive.com/clinical/movement-disorders. Episode Breakdown: __ 1:10 – Overview of phase 2 OVERTURE study 4:45 – Mechanism of action of gamma sensory stimulation  10:00 – Potential therapeutic crossover with emerging treatments 12:30 – Neurology News Minute 14:50 – Feasibility of the stimulation device 18:20– Future plans and planned phase 3 study __ * THIS EPISODE IS BROUGHT TO YOU BY , A STREAMING CHANNEL FROM MJH LIFE SCIENCES®. CHECK OUT NEW CONTENT AND SHOWS EVERY DAY, ONLY AT MEDICALWORLDNEWS.COM http://medicalworldnews.com/. The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: __ ATA188 FAILS TO MEET PRIMARY END POINT IN PHASE 2 EMBOLD STUDY OF PROGRESSIVE MS https://www.neurologylive.com/view/ata188-fails-meet-primary-end-point-phase-2-embold-study-progressive-ms ELECSYS NEUROFILAMENT LIGHT TEST GAINS BREAKTHROUGH DEVICE DESIGNATION AS WAY TO TRACK MS DISEASE ACTIVITY https://www.neurologylive.com/view/elecsys-neurofilament-light-test-gains-breakthrough-device-designation-ms-disease-activity FDA CLEARS PHASE 2 STUDY OF CAR T-CELL THERAPY KYV-101 IN MYASTHENIA GRAVIS https://www.neurologylive.com/view/fda-clears-phase-2-study-car-t-cell-therapy-kyv-101-myasthenia-gravis __ * Thanks for listening to the ® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com http://neurologylive.com/.

22m
Nov 17, 2023
FDA Greenlights Vamorolone for Duchenne Muscular Dystrophy

* Welcome to this special episode of the ® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question. In this episode, we're covering the recent approval of vamorolone (Agamree; Santhera Pharmaceuticals) oral suspension 40 mg/mL for the treatment of patients with Duchenne muscular dystrophy (DMD) aged 2 years and older. The therapy is set to be acquired by Catalyst Pharmaceuticals soon, and is a first-in-class dissociative steroid that aims to retain the anti-inflammatory activity of corticosteroids while decreasing the deleterious adverse events (AEs). We spoke with Barry J. Byrne, MD, PhD, professor and associate chair of pediatrics and director of the Powell Gene Therapy Center at the University of Florida, who discussed the recent FDA approval of Santhera Pharmaceuticals investigational agent vamorolone (now marketed as Agamree, and soon to be acquired by Catalyst Pharmaceuticals in North America), its potential to affect the treatment paradigm as a first-in-class dissociative steroid, and important efficacy and safety information from the phase 2b VISION-DMD study (NCT03439670). For more of 's coverage of vamorolone's approval, head here: FDA Approves Vamorolone as a Treatment for Duchenne Muscular Dystrophy https://www.neurologylive.com/view/fda-approves-vamorolone-agamree-duchenne-muscular-dystrophy * Episode Breakdown: __ 0:30 – Vamorolone approved for Duchenne muscular dystrophy 2:20 – Barry J. Byrne, MD, PhD, on his immediate reaction 3:25 – Safety data on vamorolone 4:00 – Byrne on the importance of bone mineralization in DMD 5:10 – Phase 2b efficacy data from VISION-DMD 5:45 – Byrne with context on the efficacy data 7:05 – Byrne with context on the landscape of DMD therapeutic development and personalization approaches __ * Thanks for listening to the Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com http://neurologylive.com/. REFERENCES 1. Catalyst Pharmaceuticals Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals. News release. Catalyst Pharmaceuticals. October 26, 2023. Accessed October 26, 2023. https://www.globenewswire.com/en/news-release/2023/10/26/2767947/13009/en/Catalyst-Pharmaceuticals-Reports-FDA-Approval-of-AGAMREE-vamorolone-for-Duchenne-Muscular-Dystrophy-Granted-to-Santhera-Pharmaceuticals.html 2. Santhera and ReveraGen announce positive and statistically highly significant topline results with vamorolone in pivotal VISION-DMD study. News release. Santhera. June 1, 2021. Accessed February 1, 2023. https://www.globenewswire.com/news-release/2021/06/01/2239124/0/en/Santhera-and-ReveraGen-Announce-Positive-and-Statistically-Highly-Significant-Topline-Results-with-Vamorolone-in-Pivotal-VISION-DMD-Study.html 3. Dang U, Guglieri M, Clemens PR, et al. Delayed start analysis of efficacy outcomes in placebo to vamorolone crossover participants in VBP15-004. Presented at MDA Clinical and Scientific Conference; March 13-16. Poster 89. 4. Muscular Dystrophy Association-Supported Drug AGAMREE® (vamorolone) Approved for the Treatment of Duchenne Muscular Dystrophy by the FDA. News release. MDA. October 26, 2023. Accessed October 26, 2023. https://www.mda.org/press-releases/mda-supported-drug-agamree-vamorolone-approved-for-the-treatment-of-duchenne-muscular-dystrophy-by-the-fda 5. Guglieri M, Clemens PR, Perlman SJ, et al. Efficacy and safety of vamorolone vs placebo and prednisone among boys with Duchenne muscular dystrophy: a randomized clinical trial. Published online August 29, 2022. doi:10.1001/jamaneurol.2022.2480

10m
Nov 07, 2023
101: Ways to Enhance Neuromodulation in Parkinsonism

* Welcome to the ® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, Alfonso Fasano, MD, PhD, professor of neurology at the University of Toronto and staff neurologist at Toronto Western Hospital, who spoke on the topic of neuromodulation in Parkinson disease and the potential targets clinicians should be learning about. He discussed the specific patient profiles who fit for neuromodulation, ways to improve this type of personalized medicine, and the needed research in this patient population going forward.  LOOKING FOR MORE MOVEMENT DISORDER DISCUSSION? CHECK OUT THE ® MOVEMENT DISORDER CLINICAL FOCUS PAGE https://www.neurologylive.com/clinical/movement-disorders. Episode Breakdown: __ 1:10 – Overview of MDS presentation 2:40 – Reasons for complexities with freezing in parkinsonism 4:35 – Aspects of deep brain stimulation care that need improvement 7:00 – Neurology News Minute 9:15 – Promising neuromodulation targets in the brain 12:35 – Finding optimal candidates for specific neurosurgery procedures 18:50 – Future research of neuromodulation in Parkinson disease __ * THIS EPISODE IS BROUGHT TO YOU BY , A STREAMING CHANNEL FROM MJH LIFE SCIENCES®. CHECK OUT NEW CONTENT AND SHOWS EVERY DAY, ONLY AT MEDICALWORLDNEWS.COM http://medicalworldnews.com/. The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: __ EISAI PLANS TO SUBMIT BLA FOR SUBCUTANEOUS LECANEMAB AFTER FINDINGS SHOW PROMISING RESULTS https://www.neurologylive.com/view/eisai-plans-submit-bla-subcutaneous-lecanemab-findings-promising-results FDA APPROVES VAMOROLONE AS A TREATMENT FOR DUCHENNE MUSCULAR DYSTROPHY https://www.neurologylive.com/view/fda-approves-vamorolone-agamree-duchenne-muscular-dystrophy SRP-9001 FAILS TO MEET PRIMARY END POINT IN PHASE 3 EMBARK STUDY https://www.neurologylive.com/view/srp-9001-fails-to-meet-primary-end-point-phase-3-embark-study __ * Thanks for listening to the ® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com http://neurologylive.com/.

25m
Nov 03, 2023
FDA Approves Zilucoplan for Myasthenia Gravis

* Welcome to this special episode of the ® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question. In this episode, we're covering the recent approval of zilucoplan (Zilbrysq; UCB Pharma) for the treatment of patients with acetylcholine receptor antibody–positive generalized myasthenia gravis. We spoke with James F. “Chip” Howard, MD, Distinguished Professor of Neuromuscular Disease and professor of neurology and medicine at The University of North Carolina at Chapel Hill School of Medicine, and the lead global investigator of the phase 3 RAISE study (NCT04115293), who discussed the downstream effects of this approval for myasthenia gravis, the available data from clinical studies, and the advantages for patients and physicians. For more of ®'s coverage of zilucoplan's approval, head here: FDA Approves Complement C5 Inhibitor Zilucoplan as Treatment for Myasthenia Gravis https://www.neurologylive.com/view/fda-approves-compliment-c5-inhibitor-zilucoplan-treatment-myasthenia-gravis * Episode Breakdown: __ 0:30 – Zilucoplan approved for AChR+ myasthenia gravis 1:40 – James F. Howard, MD, on his immediate reaction 3:30 – Safety data from the RAISE trial 4:25 – Howard on the potential advantages of zilucoplan 6:50 – Phase 3 efficacy data for zilucoplan 7:55 – Howard with context on the efficacy and the challenges with therapeutic availability in myasthenia gravis 12:10 – Howard, on the future of therapeutic development __ * Thanks for listening to the ® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com http://neurologylive.com/. REFERENCES 1. UCB announces US FDA approval of Zilbrysq (zilucoplan) for the treatment of adults with generalized myasthenia gravis. News release. October 17, 2023. Accessed October 17, 2023. https://www.ucb.com/stories-media/Press-Releases/article/UCB-announces-US-FDA-approval-of-ZILBRYSQR-zilucoplan-for-the-treatment-of-adults-with-generalized-myasthenia-gravis 2. Howard JF, Bresch S, Genge A, et al. Safety and efficacy of zilucoplan in patients with generalized myasthia gravis (RAISE): a randomized, double-blind, placebo-controlled, phase 3 study. 2023;22(5):395-406. doi:10.1016/S1474-4422(23)00080-7 3. Genge A, Hussain Y, Kaminski HJ, et al. Safety and tolerability of zilucoplan in RAISE-XT: a multicenter, open-label extension study in patients with myasthenia gravis. Presented at: MDA 2023; February 19-22; Dallas, TX. Abstract 145.

16m
Oct 23, 2023
100: 2023 ECTRIMS-ACTRIMS Meeting Highlights

* Welcome to the ® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with a variety of specialists in neurology who presented research and gave talks at MSMilan, the joint ECTRIMS-ACTRIMS meeting, held October 11-13, in Milan, Italy. Those included in this week's episode, in order of appearance, are: __ MITZI JOI WILLIAMS, MD, founder and chief executive officer of the Joi Life Wellness Group Multiple Sclerosis Center. RHONDA VOSKUHL, the director of the Multiple Sclerosis Program at UCLA. TOM FUCHS, MD, PHD, a research fellow at the MS Center at Amsterdam University Medical Center. BARRY SINGER, MD, the director and founder of The MS Center for Innovations in Care. GEORGINA ARRAMBIDE, a clinical neurologist in the MS Center of Catalunya. __ * https://www.neurologylive.com/conferences/ectrims Episode Breakdown: __ 1:10 – Joi Williams on expanding the use of biomarkers and the next steps in advancing precision medicine for multiple sclerosis treatment. 2:20 – Voskuhl on the increased research efforts to better understand the links between aging, menopause, and women with MS. 4:30 – Fuchs on the challenges of tracking cognitive decline in multiple sclerosis and improving currently available assessments. 7:50 – Singer on the introduction of biosimilars to MS care, the rigorous approval process they undergo, and the potential benefits they bring to the field. 11:45 – Arrambide on an updated consensus approach to the differential diagnosis of suspected multiple sclerosis, and the red flags clinicians should be aware of during this process. __ * THIS EPISODE IS BROUGHT TO YOU BY , A STREAMING CHANNEL FROM MJH LIFE SCIENCES®. CHECK OUT NEW CONTENT AND SHOWS EVERY DAY, ONLY AT MEDICALWORLDNEWS.COM http://medicalworldnews.com/. Thanks for listening to the ® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com http://neurologylive.com/.

15m
Oct 20, 2023
99: Understanding AMX0035's Potential in Progressive Supranuclear Palsy

* Welcome to the ® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, Gunter Hoglinger, MD, professor of neurology and translational neuroscientist at Ludwig Maximillian's University Munich, provided commentary on a newly initiated phase 3 study assessing AMX0035 (Relyrvio; Amylyx Pharmaceuticals) in patients with progressive supranuclear palsy (PSP). Otherwise known as the ORION trial, Hoglinger discussed what went into trial inclusion, primary end points, and why they believe this therapy, which was approved for patients with amyotrophic lateral sclerosis (ALS) in 2022, could have benefits in PSP.  LOOKING FOR MORE NEUROMUSCULAR DISORDER DISCUSSION? CHECK OUT THE ® NEUROMUSCULAR CLINICAL FOCUS PAGE https://www.neurologylive.com/clinical/neuromuscular. Episode Breakdown: __ 1:15 – Underlying mechanisms of progressive supranuclear palsy 3:30 – Similarities and differences between ALS and PSP 5:00 – Overview of ORION study design 7:00 – Neurology News Minute 9:15 – Reasons behind specific trial inclusion 10:35 – Primary end points of the study  12:50 – Significance of a potentially successful trial __ * THIS EPISODE IS BROUGHT TO YOU BY , A STREAMING CHANNEL FROM MJH LIFE SCIENCES®. CHECK OUT NEW CONTENT AND SHOWS EVERY DAY, ONLY AT MEDICALWORLDNEWS.COM http://medicalworldnews.com/. The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: __ FDA ADVISORY COMMITTEE DOWNVOTES MESENCHYMAL STEM CELL APPROACH NUROWN AS POTENTIAL ALS THERAPY https://www.neurologylive.com/view/fda-advisory-committee-downvotes-mesenchymal-stem-cell-approach-nurown-as-potential-als-therapy FDA APPROVES HONEYNAPS’ ARTIFICIAL INTELLIGENCE SLEEP DISORDER DIAGNOSIS SOFTWARE https://www.neurologylive.com/view/fda-approves-honeynaps-artificial-intelligence-sleep-disorder-diagnosis-software FDA APPROVES CIPAGLUCOSIDASE ALFA AND MIGLUSTAT AS FIRST TWO-COMPONENT THERAPY FOR POMPE DISEASE https://www.neurologylive.com/view/fda-approves-cipaglucosidase-alfa-miglustat-first-two-component-therapy-pompe __ * Thanks for listening to the ® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com http://neurologylive.com/.

15m
Oct 05, 2023
98: Uncovering Phenotypical Features of Narcolepsy Type 1

* Welcome to the ® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, Birgitte R. Kornum, MD, an associate professor in the department of neuroscience at the University of Copenhagen, discussed recently published preclinical research assessing phenotypical features and disease progression of narcolepsy type 1. Kornum provided insight on the 2 mouse models used, the effectiveness of the DVC System, and some of the phenotypic features identified. In addition, she gave insight on how the research adds to the ongoing puzzle of treating narcolepsy and where future efforts should be directed toward. LOOKING FOR MORE MOVEMENT DISORDER DISCUSSION? CHECK OUT THE ® NARCOLEPSY CLINICAL FOCUS PAGE https://www.neurologylive.com/disease-spotlight/disease-spotlight-narcolepsy. Episode Breakdown: __ 1:15 – Overview of Medicare study and objectives 3:15 – Advantages of DVC System 5:40 – Clinical takeaways from the findings 9:30 – Neurology News Minute 12:05 – Critical phenotypic features of narcolepsy  14:20 – Significance of this research, future goals __ * THIS EPISODE IS BROUGHT TO YOU BY , A STREAMING CHANNEL FROM MJH LIFE SCIENCES®. CHECK OUT NEW CONTENT AND SHOWS EVERY DAY, ONLY AT MEDICALWORLDNEWS.COM http://medicalworldnews.com/. The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: __ ALZHEIMER AGENT ALZ-801 IMPROVES COGNITION, REDUCES RELEVANT BIOMARKER LEVELS IN 2-YEAR ANALYSIS https://www.neurologylive.com/view/alzheimer-alz-801-improves-cognition-reduces-biomarker-levels-2-year-analysis FDA UPDATES LABEL FOR PSYCHOSIS MEDICATION PIMAVANSERIN https://www.neurologylive.com/view/fda-updates-label-psychosis-medication-pimavanserin FDA APPROVES AI-INCORPORATED ALZHEIMER DETECTION SOFTWARE AIRASCORE https://www.neurologylive.com/view/fda-approves-ai-incorporated-alzheimer-detection-software-airascore __ * Thanks for listening to the ® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com http://neurologylive.com/.

17m
Sep 22, 2023
97: Identifying Gaps in Access to Parkinson Disease Care

* Welcome to the ® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, James Beck, PhD, senior vice president and chief scientific officer of the Parkinson's Foundation provided perspectives on a recently published Medicare claims study that highlighted major gaps and disparities in access to Parkinson disease care. He spoke on the significance of the findings, including the lack of movement disorder specialists and issues with access to mental health professionals despite high rates of depression in this patient population. Furthermore, he spoke on the ways to make specialized care for Parkinson disease more obtainable, especially for those in rural or underserved communities. LOOKING FOR MORE MOVEMENT DISORDER DISCUSSION? CHECK OUT THE ® MOVEMENT DISORDER CLINICAL FOCUS PAGE https://www.neurologylive.com/clinical/movement-disorders. Episode Breakdown: __ 1:15 – Overview of Medicare study and objectives 2:20 – Greatest clinical take-home points from the data 4:15 – Utilizing resources to cover gaps in access 5:30 – Neurology News Minute 8:05 – Reasons for lack of mental health professional support 10:55 – Challenges with understanding depression in PD 12:35 – Ensuring access to PD care in rural/underserved communities __ * THIS EPISODE IS BROUGHT TO YOU BY , A STREAMING CHANNEL FROM MJH LIFE SCIENCES®. CHECK OUT NEW CONTENT AND SHOWS EVERY DAY, ONLY AT MEDICALWORLDNEWS.COM http://medicalworldnews.com/. The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: __ FDA APPROVES SANDOZ’S NATALIZUMAB-SZTN AS FIRST BIOSIMILAR FOR MULTIPLE SCLEROSIS https://www.neurologylive.com/view/fda-approves-sandoz-natalizumab-sztn-tyruko-first-biosimilar-multiple-sclerosis DUCHENNE AGENT PAMREVLUMAB FAILS TO MEET PRIMARY END POINT IN PHASE 3 LELANTOS-2 TRIAL https://www.neurologylive.com/view/duchenne-agent-pamrevlumab-fails-meet-primary-end-point-phase-3-lelantos-2-trial FDA ISSUES RAVULIZUMAB COMPLETE RESPONSE LETTER FOR NMOSD, CITING NEEDED CHANGES TO REMS PROGRAM https://www.neurologylive.com/view/fda-issues-ravulizumab-complete-response-letter-nmosd-citing-needed-changes-rems-program __ * Thanks for listening to the ® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com http://neurologylive.com/.

16m
Sep 08, 2023
96: Complexities With Cognitive Screening in Primary Care Settings

* Welcome to the ® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, Nicole Fowler, PhD, director of research for internal medicine and geriatrics at Indiana University School of Medicine, discussed the DAVOS Alzheimer's Collaborative DIGITAL Demonstration Project, an initiative to help understand the feasibility, acceptability, and implementation of digital cognitive screening tools in primary care settings. Specifically, she spoke on how these tools will be used as more novel therapeutics for Alzheimer disease emerge, the challenges with screening patients large-scale, and how blood tests and other biomarkers will play a role going forward. LOOKING FOR MORE ALZHEIMER DISEASE/DEMENTIA DISCUSSION? CHECK OUT THE ® ALZHEIMER DISEASE/DEMENTIA CLINICAL FOCUS PAGE https://www.neurologylive.com/clinical/dementia-alzheimer. Episode Breakdown: __ 1:15 – Objectives of DAVOS Project, overview of presentation from AAIC 6:55 – Complexities and challenges with screening in primary care settings 10:30 – Neurology News Minute 13:25 – Incorporating screening procedures with emerging therapies 12:30 – Future role of digital technologies and blood tests __ * THIS EPISODE IS BROUGHT TO YOU BY , A STREAMING CHANNEL FROM MJH LIFE SCIENCES®. CHECK OUT NEW CONTENT AND SHOWS EVERY DAY, ONLY AT MEDICALWORLDNEWS.COM http://medicalworldnews.com/. The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: __ FDA APPROVES EXPANDED INDICATION OF DAXIBOTULINUMTOXINA TO TREAT CERVICAL DYSTONIA https://www.neurologylive.com/view/fda-approves-expanded-indication-daxibotulinumtoxina-treat-cervical-dystonia EXON 44 SKIPPING AGENT AOC 1044 GRANTED FDA ORPHAN DRUG DESIGNATION FOR DUCHENNE MUSCULAR DYSTROPHY https://www.neurologylive.com/view/exon-44-skipping-aoc-1044-fda-orphan-drug-designation-dmd CGRP MEDICATION ATOGEPANT GAINS EUROPEAN COMMISSION APPROVAL AS MIGRAINE PREVENTIVE https://www.neurologylive.com/view/cgrp-medication-atogepant-european-commission-approval-migraine-preventive FDA APPROVES NEUROCRINE BIOSCIENCES’ VALBENAZINE FOR HUNTINGTON DISEASE CHOREA https://www.neurologylive.com/view/fda-approves-neurocrine-biosciences-valbenazine-huntington-disease-chorea __ * Thanks for listening to the ® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com http://neurologylive.com/.

22m
Aug 25, 2023
Addition of Valbenazine to Treat Huntington Disease Chorea

* Welcome to this special episode of the ® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question. In this episode, we're covering the recent expanded indication of valbenazine (Ingrezza; Neurocrine Biosciences) to include the treatment of chorea associated with Huntington disease (HD). Erin Furr-Stimming, MD, FAAN, FANA, a professor of neurology at McGovern Medical School of UTHealth Houston, and principal investigator of the phase 3 KINECT-HD studies, valbenazine's supportive studies, offered her immediate reaction to the news. In addition, she spoke about the efficacy observed in these trials, the advantages valbenazine has as a VMAT2 inhibitor, and the remaining unmet needs in the management of HD.   For more of ®'s coverage of valbenazine's expanded indication, head here: FDA Approves Neurocrine Biosciences’ Valbenazine for Huntington Disease Chorea https://www.neurologylive.com/view/fda-approves-neurocrine-biosciences-valbenazine-huntington-disease-chorea * Episode Breakdown: __ 0:30 – Valbenazine approved for Huntington disease chorea 1:35 – Erin Furr-Stimming, MD, FAAN, FANA, on immediate reaction 2:15 – Treatment toolbox for HD chorea  3:05 – Furr-Stimming on mechanistic advantages of valbenazine 5:10 – Phase 3 efficacy data of valbenazine 5:55 – Furr-Stimming on greatest clinical takeaways from trials 6:55 – Current state of Huntington management 8:00 – Furr-Stimming on current unmet needs for patients, including research on disease-modifying therapies __ * Thanks for listening to the ® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com http://neurologylive.com/. REFERENCES 1. Neurocrine Biosciences Announces FDA Approval of INGREZZA® (valbenazine) Capsules for the Treatment of Chorea Associated With Huntington's Disease. News Release. Neurocrine Biosciences. Published August 18, 2023. Accessed August 21, 2023.

11m
Aug 21, 2023
95: Expanding Potential for Long-Term Treatment in SMA

* Welcome to the ® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, Thomas Crawford, MD, a pediatric neurologist at Johns Hopkins Medicine, spoke on the recently published 5-year analysis of the NURTURE study (NCT02386553), a long-term trial assessing the efficacy and safety of nusinersen (Spinraza; Biogen) in presymptomatic infants with spinal muscular atrophy (SMA). Crawford discussed the significance of the positive findings, the shift in conversations around treatment optimization in SMA, and how subgroup data may factor into the design of future trials. LOOKING FOR MORE NEUROMUSCULAR DISORDERS DISCUSSION? CHECK OUT THE ® NEUROMUSCULAR CLINICAL FOCUS PAGE https://www.neurologylive.com/clinical/neuromuscular. Episode Breakdown: __ 1:20 – Benefits seen with nusinersen in NURTURE  4:10 – Changes in goals for treating SMA 6:05 – Complexities with getting infants therapy days after diagnosis 9:40 – Neurology News Minute 12:30 – Subgroup findings from NURTURE 15:20 – Ways to improve treatment optimization in SMA __ * THIS EPISODE IS BROUGHT TO YOU BY , A STREAMING CHANNEL FROM MJH LIFE SCIENCES®. CHECK OUT NEW CONTENT AND SHOWS EVERY DAY, ONLY AT MEDICALWORLDNEWS.COM http://medicalworldnews.com/. The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: __ __ * Thanks for listening to the ® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com http://neurologylive.com/.

23m
Aug 11, 2023
94: The Discussion Surrounding Lecanemab's Approval for Alzheimer Disease

* Welcome to the ® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. This episode features an in-depth dive into the recent approval of lecanemab (Leqembi; Eisai) for Alzheimer disease and the ongoing debate about its potential benefit, the amyloid-targeting class of medicines, and the communication of data. Featured in this episode is commentary from 2 experts in neurology clinical care: Anton P. Porsteinsson, MD, the William B. and Sheila Konar Professor of Psychiatry, Neurology, Neuroscience, and Medicine, and the director of the Alzheimer's Disease Care, Research and Education Program at the University of Rochester School of Medicine and Dentistry; and Alberto Espay, MD, PhD, the division director and Research Endowed Chair of the James J. and Joan A. Gardner Family Center for Parkinson’s Disease and Movement Disorders, and a professor of clinical neurology and rehabilitation medicine at the University of Cincinnati. LOOKING FOR MORE ALZHEIMER DISEASE DISCUSSION? CHECK OUT THE ® DEMENTIA AND ALZHEIMER DISEASE CLINICAL FOCUS PAGE https://www.neurologylive.com/clinical/dementia-alzheimer. Episode Breakdown: __ 1:45 – Introduction and main findings 3:15 – Espay, with his perspective on the downstream effects of the approval 10:10 – Porsteinsson, with his perspective on the downstream effects of the approval 18:30 – Secondary end points and safety data 20:05 – Porsteinsson, on the recent progress in AD 23:05 – Espay, on contextualizing the effect of amyloid clearance 26:00 – Porsteinsson, on the logistics of the approval 34:20 – Espay, on the lingering unanswered questions 38:20 – Espay, on the communication of data to the public around the amyloid therapies 42:25 – Porsteinsson, on how things evolve going forward __ * THIS EPISODE IS BROUGHT TO YOU BY , A STREAMING CHANNEL FROM MJH LIFE SCIENCES®. CHECK OUT NEW CONTENT AND SHOWS EVERY DAY, ONLY AT MEDICALWORLDNEWS.COM http://medicalworldnews.com/. The stories and studies featured in this week's show, as well as additional expert interviews on lecanemab, can be found here: SHOW NOTES: __ __ * ADDITIONAL READING AND COVERAGE: __ __ * ADDITIONAL EXPERT INTERVIEWS: __ David Bates, PhD: Downstream Impacts of Lecanemab on Alzheimer Disease, Future Drug Development https://www.neurologylive.com/view/downstream-impacts-lecanemab-alzheimer-disease-future-drug-development Howard Fillit, MD: Lecanemab’s Impact on Care and Diagnosis and the Future of Alzheimer Disease Treatment https://www.neurologylive.com/view/lecanemab-impact-care-diagnosis-future-alzheimer-disease-treatment Nicole Fowler, PhD, MHSA: Preparing Primary Care Centers for New Wave of Alzheimer Agents https://www.neurologylive.com/view/preparing-primary-care-centers-for-new-wave-alzheimer-agents-nicole-fowler Ronald C. Petersen, MD, PhD: Lessons Learned About Clinically Meaningful Benefit from Antiamyloid Trials https://www.neurologylive.com/view/lessons-learned-about-clinically-meaningful-benefit-from-antiamyloid-trials-ronald-c-petersen Sharon Cohen, MD, FRCPC: Significance of Expanding Antiamyloid Therapy Class, Toolbox to Treat Alzheimer https://www.neurologylive.com/view/significance-expanding-antiamyloid-therapy-class-toolbox-to-treat-alzheimer-sharon-cohen __ * Thanks for listening to the ® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com http://neurologylive.com/. REFERENCES 1. FDA Converts Novel Alzheimer’s Disease Treatment to Traditional Approval. FDA. News release. July 6, 2023. Accessed July 27, 2023. https://www.fda.gov/news-events/press-announcements/fda-converts-novel-alzheimers-disease-treatment-traditional-approval 2. van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer’s disease. 2023;388:9-21. doi:10.1056/NEJMoa2212948 3. Sims JR, Zimmer JA, Evans CD, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. . Published online July 17, 2023. doi:10.1001/jama.2023.13239

47m
Jul 28, 2023
93: Caring for Women With Parkinson Disease

* Welcome to the ® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with Jill Farmer, DO, MPH https://www.neurologylive.com/authors/jill-m-giordano-farmer-do-mph, an assistant professor of neurology and director of the Parkinson’s Disease & Movement Disorder Program at Global Neurosciences Institute, who spoke with us about the current landscape of care for women with Parkinson disease (PD), how the approach to their care can differ from men, the major gaps around education and treatment for these women, and much more. LOOKING FOR MORE MOVEMENT DISORDER DISCUSSION? CHECK OUT THE ® MOVEMENT DISORDER CLINICAL FOCUS PAGE https://www.neurologylive.com/clinical/movement-disorders. Episode Breakdown: __ 1:15 – The presentation of Parkinson disease for women 3:00 – Nonmotor symptoms that can create challenges for diagnosis 4:45 – OFF episodes and dyskinesia in women vs men 7:00 – Being attentive to patient needs in treatment 10:20 – The daily impact of Parkinson disease 13:05 – Neurology News Minute 16:30 – Encouraging women with Parkinson to participate in trials 18:30 – Barriers to care specific to women 20:00 – Communication with women patients 22:20 – Areas of need for research 23:35 – Conversations in areas of limited knowledge 25:20 – Closing thoughts __ * THIS EPISODE IS BROUGHT TO YOU BY , A STREAMING CHANNEL FROM MJH LIFE SCIENCES®. CHECK OUT NEW CONTENT AND SHOWS EVERY DAY, ONLY AT MEDICALWORLDNEWS.COM http://medicalworldnews.com/. The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: __ __ * Thanks for listening to the ® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com http://neurologylive.com/.

28m
Jul 14, 2023
92: Highlights From the 2023 CMSC, SLEEP, AHS, and ATMRD Annual Meetings

* Welcome to the ® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with a variety of specialists in neurology who presented research and gave talks at 4 recent major medical meetings—the Consortium of MS Centers Annual Meeting, the Annual Joint SLEEP Meeting, the Advanced Therapeutics in Movement and Related Disorders Congress, and the American Headache Society’s Annual Scientific Meeting. Those included in this week's episode, in order of appearance, are: __ AMIT BAR-OR, MD, FRCPC, FAAN, FANA, the Melissa and Paul Anderson President’s Distinguished Professor at the Perelman School of Medicine of the University of Pennsylvania. GAVIN GIOVANNONI, MBBCH, PHD, FCP, FRCP, PRCPATH BAR-OR, MD, FRCPC, FAAN, FANA, a professor of neurology at Barts and The London School of Medicine and Dentistry. DAYNA JOHNSON, PHD, MPH, MSW, MS, a sleep epidemiologist and assistant professor at the Rollins School of Public Health at Emory University. JOHN WINKELMAN, MD, PHD, the chief of the Sleep Disorders Clinical Research Program at Massachusetts General Hospital. LAXMAN BAHROO, DO, a professor of neurology and the residency program director at MedStar Georgetown University Hospital. LING WAN-ALBERT, OTD, OD/OTR/L, an assistant professor of occupational therapy at the New York Institute of Technology. SARA PAVITT, MD, the chief of headache at UT Austin Dell Children’s Hospital. ALI EZZATI, MD, the director of the Neuroinformatics Program at the University of California, Irvine. __ * ® https://www.neurologylive.com/conferences/aan. Episode Breakdown: __ 1:15 – Bar-Or on the potential of BTK inhibition in multiple sclerosis at CMSC 2023 4:40 – Giovannoni on the understanding of MS as a smoldering disease at CMSC 2023 10:30 – Johnson on multilevel efforts to address modifiable factors of sleep health at SLEEP 2023 13:05 – Winkelman on moving away from dopamine agonists as first-line treatments for restless legs syndrome at SLEEP 2023 15:30 – Bahroo on the role of botulinumtoxins in Parkinson disease care at ATMRD 2023 19:00 – Wan-Albert on the impact of social isolation on cognition at ATMRD 2023 22:10 – Pavitt on the universal knowledge about pediatric headache for neurologists and nonspecialists at AHS 2023 24:05 – Ezzati on the use of machine learning models to improve treatment optimization in heterogenous migraine at AHS 2023 __ * THIS EPISODE IS BROUGHT TO YOU BY , A STREAMING CHANNEL FROM MJH LIFE SCIENCES®. CHECK OUT NEW CONTENT AND SHOWS EVERY DAY, ONLY AT MEDICALWORLDNEWS.COM http://medicalworldnews.com/. Thanks for listening to the ® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com http://neurologylive.com/.

28m
Jun 30, 2023
Special Episode: SRP-9001 Approved As First Gene Therapy for Duchenne Muscular Dystrophy

* Welcome to this special episode of the ® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question. In this episode, we're covering the recent approval of SRP-9001, or delandistrogene moxeparvovec (Elevidys; Sarepta) in Duchenne muscular dystrophy (DMD). Offering commentary is Natalie Goedeker, CPNP, a nurse practitioner in neurology in the Neuromuscular Division at Washington University in St Louis. SRP-9001 is an AAV vector-based gene therapy that was approved for the treatment of ambulatory patients with DMD with a confirmed mutation in the gene aged 4 to 5 years, based on data from the phase 3 EMBARK study (NCT05096221). For more of ®'s coverage of SRP-9001's approval, head here: FDA Approves SRP-9001 as First Gene Therapy for Duchenne Muscular Dystrophy https://www.neurologylive.com/view/fda-approves-srp-9001-first-gene-therapy-for-duchenne-muscular-dystrophy * Episode Breakdown: __ 0:30 – SRP-9001 (Elevidys; Sarepta) is approved for DMD 1:35 – Natalie Goedeker, CPNP, on the approval 3:05 – Efficacy of SRP-9001 4:00 – Goedeker on pieces of efficacy data released 4:45 – Currently available therapies for DMD 5:35 – Goedeker on role of SRP-9001 in treatment landscape 6:55 – Safety data of SRP-9001 8:00 – Goedeker on safety considerations of which prescribing clinicians should be aware __ * Thanks for listening to the ® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com http://neurologylive.com/. REFERENCES 1. Sarepta Therapeutics announces FDA approval of Elevidys, the first gene therapy to treat Duchenne muscular dystrophy. News release. June 22, 2023. Accessed June 22, 2023. https://www.businesswire.com/news/home/20230622454844/en/

12m
Jun 22, 2023
91: Assessing the Landscape of Sleep Disorder Care

* Welcome to the ® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with Ann Marie Morse, DO, FAAN, a pediatric neurologist and sleep medicine specialist at Geisinger Medical Center, who sat down with at the annual SLEEP meeting to discuss the landscape of challenges narcolepsy-related challenges that patients face, the influence of gut health on sleep apnea, how nighttime disruptions can affect treatment decisions, emerging concepts of care, and much more. LOOKING FOR MORE SLEEP DISORDER DISCUSSION? CHECK OUT THE ® SLEEP DISORDER CLINICAL FOCUS PAGE https://www.neurologylive.com/clinical/stroke. Episode Breakdown: __ 1:15 – Factors at play in obstructive sleep apnea 3:40 – Literature on the gut microbiome's role in sleep 5:55 – Lingering needs in narcolepsy treatment 8:30 – Neurology News Minute 12:40 – The effect of disrupted nighttime sleep 15:45 – Emerging concepts in sleep medicine __ * THIS EPISODE IS BROUGHT TO YOU BY , A STREAMING CHANNEL FROM MJH LIFE SCIENCES®. CHECK OUT NEW CONTENT AND SHOWS EVERY DAY, ONLY AT MEDICALWORLDNEWS.COM http://medicalworldnews.com/. The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: __ __ * Thanks for listening to the ® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com http://neurologylive.com/.

19m
Jun 16, 2023
90: Raising Stroke Awareness and Improving Clinical Care

* Welcome to the ® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with Brandon Giglio, MD, a vascular neurologist and clinical assistant professor of neurology at NYU Grossman School of Medicine, as well as the director of Vascular Neurology at NYU Langone Hospital in Brooklyn, New York. As May is annually designated as Stroke Awareness Month in the United States, Giglio sat down with us to extend that time of awareness and share his insight into the current public understanding of stroke, how effective the care paradigm is at prevention and poststroke care, and much more. LOOKING FOR MORE STROKE DISCUSSION? CHECK OUT THE ® STROKE CLINICAL FOCUS PAGE https://www.neurologylive.com/clinical/stroke. Episode Breakdown: __ 1:15 – Breaking down the signs and symptoms of stroke with B.E. F.A.S.T 2:45 – The importance of stroke awareness 3:55 – Treating patients with poststroke symptoms 5:45 – Neurology News Minute 10:40 – Notable risk factors for stroke 13:15 – The critical need for novel education tools in stroke __ * THIS EPISODE IS BROUGHT TO YOU BY , A STREAMING CHANNEL FROM MJH LIFE SCIENCES®. CHECK OUT NEW CONTENT AND SHOWS EVERY DAY, ONLY AT MEDICALWORLDNEWS.COM http://medicalworldnews.com/. The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: __ POTENTIAL PATH FOR PHASE 3 STUDY OF AOC 1001 IN MYOTONIC DYSTROPHY BECOMES CLEAR AFTER FDA EASE’S CLINICAL HOLD https://www.neurologylive.com/view/potential-path-for-phase-3-study-aoc-1001-myotonic-dystrophy-becomes-clear-after-fda-clinical-hold FDA GRANTS FAST TRACK DESIGNATION FOR ATRIAL FIBRILLATION THERAPY ASUNDEXIAN https://www.neurologylive.com/view/fda-grants-fast-track-designation-atrial-fibrillation-therapy-asundexian FDA PUSHES BACK DECISION DATE FOR DUCHENNE GENE THERAPY SRP-9001 https://www.neurologylive.com/view/fda-pushes-back-decision-date-for-duchenne-gene-therapy-srp-9001 FDA ACCEPTS NDA FOR DHE NASAL POWDER PRODUCT STS101 FOR ACUTE MIGRAINE https://www.neurologylive.com/view/fda-accepts-nda-for-dhe-nasal-powder-product-sts101-acute-migraine CMS ANNOUNCES PLAN TO PROVIDE COVERAGE OF ANTIAMYLOID THERAPIES FOR ALZHEIMER DISEASE https://www.neurologylive.com/view/cms-announces-plan-provide-coverage-antiamyloid-therapies-for-alzheimer-disease __ * Thanks for listening to the ® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com http://neurologylive.com/.

17m
Jun 02, 2023
89: Potential of CNM-Au8, Gold Nanocrystals to Treat ALS

* Welcome to the ® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with James Berry, MD, PhD, director of the Massachusetts General Hospital ALS Care Center. At the 2023 American Academy of Neurology Annual Meeting, he spoke about new data from a study assessing CNM-Au8, a nanocrystal formulation in development for patients with ALS and other neurological diseases. Additionally, he talked about the current unmet needs in the ALS community, including the need for more diverse treatment options and increased research.  LOOKING FOR MORE MULTIPLE SCLEROSIS DISCUSSION? CHECK OUT THE ® NEUROMUSCULAR CLINICAL FOCUS PAGE https://www.neurologylive.com/clinical/neuromuscular. Episode Breakdown: __ 1:15 – Clinical development program of CNM-Au8 3:40 – Safety findings, treatment responses of CNM-Au8 4:20 – Next steps in research  6:25 – Neurology News Minute 8:45 – Conducting safe trials  10:00 – Remaining unmet needs for patients with ALS 11:15 – Need for additional research __ * THIS EPISODE IS BROUGHT TO YOU BY , A STREAMING CHANNEL FROM MJH LIFE SCIENCES®. CHECK OUT NEW CONTENT AND SHOWS EVERY DAY, ONLY AT MEDICALWORLDNEWS.COM http://medicalworldnews.com/. The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: __ FDA APPROVES BREXPIPRAZOLE AS FIRST THERAPY FOR ALZHEIMER AGITATION https://www.neurologylive.com/view/fda-approves-brexpiprazole-first-therapy-for-alzheimer-agitation FDA PANEL VOTES IN FAVOR OF GENE THERAPY SRP-9001 FOR DUCHENNE MUSCULAR DYSTROPHY IN TIGHT DECISION https://www.neurologylive.com/view/fda-panel-votes-in-favor-of-gene-therapy-srp-9001-for-duchenne-muscular-dystrophy ALZHEIMER AGENT COYA 301 HALTS COGNITIVE DECLINE, RESTORES REGULATORY T CELL DYSFUNCTION IN PHASE 1 STUDY https://www.neurologylive.com/view/alzheimer-agent-coya-301-halts-cognitive-decline-restores-regulatory-t-cell-dysfunction-phase-1-study PHASE 2 DATA HIGHLIGHT FENEBRUTINIB'S IMPACT ON BRAIN LESIONS IN RELAPSING MULTIPLE SCLEROSIS https://www.neurologylive.com/view/phase-2-data-highlight-fenebrutinib-impact-brain-lesions-in-relapsing-multiple-sclerosis __ * Thanks for listening to the ® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com http://neurologylive.com/. REFERENCES 1. Berry J, Maragakis N, Paganoni S, et al. Evidence for Survival Benefit in ALS with CNM-Au8 Treatment Across Three Study Populations. Presented at: 2023 AAN Annual Meeting; April 22-27, Boston, Massachusetts.

13m
May 19, 2023
88: 2023 AAN Annual Meeting Highlights

* Welcome to the ® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with a variety of specialists in neurology who presented research and gave talks at the 75th American Academy of Neurology Annual Meeting, held April 22-27, 2023, in Boston, Massachusetts. Those included in this week's episode, in order of appearance, are: __ MICHAEL H. BARNETT, MBBS, PHD, FRACP, a consultant neurologist at Royal Prince Alfred Hospital (RPAH) Sydney, director of the RPAH MS Clinic and the MS Clinical Trials Unit at the Brain and Mind Centre; codirector of the MS Research Australia Brain Bank; and a senior professor at the University of Sydney. NANCY R. FOLDVARY-SCHAEFER, DO, FAAN, the director of the Sleep Disorders Center and staff in the Epilepsy Center at Cleveland Clinic, and a professor of medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. SEAN J. PITTOCK, MD, the director of the Center for Multiple Sclerosis and Autoimmune Neurology and director of the Neuroimmunology Research Laboratory at Mayo Clinic. KATHERINE W. TURK, MD, a neurologist at Boston VA Memory Disorders Clinic, principal investigator and codirector of the Center for Translational Cognitive Neuroscience lab (CTCN) at VA Boston; and assistant professor of neurology and coleader of the Outreach, Recruitment and Engagement core of the Alzheimer’s Disease Research Center at Boston University. ERIKA U. AUGUSTINE, MD, MS, the associate chief science officer and director of the Clinical Trials Unit at the Kennedy Krieger Institute. JEFFREY M. STATLAND, MD, a neuromuscular disease specialist and professor of neurology at the University of Kansas Medical Center. CHIAN-CHUN CHIANG, MD, a stroke and migraine specialist and assistant professor of neurology at Mayo Clinic. __ * ® https://www.neurologylive.com/conferences/aan. Episode Breakdown: __ 1:10 – Barnett on the topline findings for CNM-Au8 from the VISIONARY-MS clinical trial. 8:35 – Foldvary-Schaefer on the understanding of the relationship between epilepsy and sleep. 13:25 – Pittock on the latest data on ravulizumab from the CHAMPION-NMOSD trial. 19:00 – Turk on the landscape of diagnosis and treatment for mild cognitive impairment, and how to improve the process. 22:00 – Augustine on Dr. Sidney Carter and the current paradigm of care in child neurology. 27:15 – Statland on the findings for ataluren in nonsense mutation Duchenne muscular dystrophy from Study 041. 34:05 – Chiang on the takeaways from a big data analysis of 25 therapies for acute migraine management. __ * THIS EPISODE IS BROUGHT TO YOU BY , A STREAMING CHANNEL FROM MJH LIFE SCIENCES®. CHECK OUT NEW CONTENT AND SHOWS EVERY DAY, ONLY AT MEDICALWORLDNEWS.COM http://medicalworldnews.com/. Thanks for listening to the ® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com http://neurologylive.com/. REFERENCES 1. Barnett MH. VISIONARY-MS Top-line Results: A Phase 2, Randomized, Double-Blind, Parallel Group, Placebo-controlled Study to Assess the Safety and Efficacy of CNM-Au8, a Catalytically Active Gold Nanocrystal Suspension in Relapsing Multiple Sclerosis. Presented at: AAN Annual Meeting; April 22-27, 2023; Boston, MA. 2. Foldvary-Schaefer NR. Diagnostic Testing: Beyond the MSLT. Presented at: AAN Annual Meeting; April 22-27, 2023; Boston, MA. 3. Pittock SJ. Efficacy and safety of ravulizumab in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: outcomes from the phase 3 CHAMPION-NMOSD trial. Presented at: AAN Annual Meeting; April 22-27, 2023; Boston, MA. 4. Statland JM. Safety and Efficacy of Ataluren in nmDMD Patients from Study 041, a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial. Presented at: AAN Annual Meeting; April 22-27, 2023; Boston, MA. 5. Chiang CC. Simultaneous Comparisons of 25 Acute Migraine Medications: A Big Data Analysis of 10 Million Patient Self-Reported Treatment Records From A Migraine Smartphone Application. Presented at: AAN Annual Meeting; April 22-27, 2023; Boston, MA.

41m
May 05, 2023
Special Episode: Tofersen Approved for SOD1 ALS

* Welcome to this special episode of the ® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question. In this episode, we're covering the recent approval of tofersen (Qalsody; Biogen/Ionis) in mutation-mediated amyotrophic lateral sclerosis (ALS). Offering commentary is Angela Genge, MD, FRCPC, the director of the ALS Centre of Excellence for Research and Patient Care at McGill University, and an executive at the Clinical Research Unit at The Neuro (Montreal Neurological Institute-Hospital). Tofersen is an antisense oligonucleotide, and its new drug application (NDA) was supported by data from a phase 1 study of healthy volunteers, a phase 1/2 dose-ascending study, the pivotal phase 3 VALOR study (NCT02623699), and its open-label extension. For more of ®'s coverage of tofersen's approval, head here: FDA Approves Tofersen as First SOD1-ALS Treatment https://www.neurologylive.com/view/fda-approves-tofersen-first-sod1-als-therapy * Episode Breakdown: __ 0:30 – Tofersen (Qalsody; Biogen/Ionis) approved for SOD1-ALS 1:35 – Angela Genge, MD, FRCPC, on the approval 3:05 – The implications of targeting a root cause of ALS 5:00 – Data from the supporting VALOR study 5:55 – Genge on the context around the trial data 7:35 – Questions about access to tofersen amid accelerated approval __ * Thanks for listening to the ® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com http://neurologylive.com/. REFERENCES 1. FDA approves treatment of amyotrophic lateral sclerosis associated with a mutation in the SOD1 gene. News release. FDA. April 25, 2023. Accessed April 25, 2023. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-amyotrophic-lateral-sclerosis-associated-mutation-sod1-gene 2. Miller TM, Cudkowicz ME, Genge A, et al. Trial of antisense oligonucleotide tofersen for SOD1 ALS. . 2022;387:1099-1110. doi:10.1056/NEJMoa2204705.

12m
Apr 25, 2023
87: Severe Multiple Sclerosis and the CASA-MS Study

* Welcome to the ® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with with Robert Zivadinov, MD, PhD, director of the Buffalo Neuroimaging Analysis Center https://www.neurologylive.com/sap-partner/bnac, and a professor of neurology and biomedical informatics at the Jacobs School of Medicine & Biomedical Sciences at the University at Buffalo. He discussed the recent CASA-MS study that he and colleagues conducted into a subgroup of patients with multiple sclerosis (MS) who develop rapid and progressive disability at a relatively young age, which he presented earlier this year at the 2023 Americas Committee for Treatment and Research in MS Forum, and the critical effectively need to treat this group of patients. The study was carried out at The Boston Home, a specialized residential facility for individuals with advanced progressive neurological disorders, in Dorchester, Massachusetts, and at the University at Buffalo, in New York. LOOKING FOR MORE MULTIPLE SCLEROSIS DISCUSSION? CHECK OUT THE ® MULTIPLE SCLEROSIS CLINICAL FOCUS PAGE https://www.neurologylive.com/clinical/multiple-sclerosis. Episode Breakdown: __ 1:10 – Background on the CASA-MS study subpopulation 3:45 – Topline results of the study 6:05 – The need for further clarification in MS populations 7:10 – The utility of biomarkers such as GFAP 12:15 – Further assessment plans for the CASA-MS cohort 14:15 – Neurology News Minute 18:35 – Access to the tools to characterize progressive MS 21:30 – The potential with portable MRI and artificial intelligence 25:25 – Unmet needs in progressive MS __ * THIS EPISODE IS BROUGHT TO YOU BY , A STREAMING CHANNEL FROM MJH LIFE SCIENCES®. CHECK OUT NEW CONTENT AND SHOWS EVERY DAY, ONLY AT MEDICALWORLDNEWS.COM http://medicalworldnews.com/. The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: __ PHASE 3 STUDY OF GTX-104 IN SUBARACHNOID HEMORRHAGE EXPECTED TO PROCEED FOLLOWING FDA FEEDBACK https://www.neurologylive.com/view/phase-3-study-of-gtx-104-subarachnoid-hemorrhage-expected-to-proceed-following-fda-feedback FDA PLACES PARTIAL HOLD ON EVOBRUTINIB INITIATION IN NEWLY ENROLLED PATIENTS WITH MS https://www.neurologylive.com/view/fda-places-partial-hold-on-evobrutinib-initiation-in-newly-enrolled-patients-with-ms FDA PANEL VOTES IN FAVOR OF BREXPIPRAZOLE AS POTENTIAL THERAPY FOR ALZHEIMER AGITATION https://www.neurologylive.com/view/fda-panel-votes-in-favor-of-brexpiprazole-as-potential-therapy-for-alzheimer-agitation FDA APPROVES INTELGENX AND GENSCO'S RIZATRIPTAN FOR ACUTE MIGRAINE TREATMENT https://www.neurologylive.com/view/fda-approves-intelgenx-and-gensco-s-rizatriptan-for-acute-migraine-treatment DEA RULES FENFLURAMINE NO LONGER A CONTROLLED SUBSTANCE https://www.neurologylive.com/view/dea-rules-fenfluramine-no-longer-controlled-substance ATOGEPANT’S INDICATION EXPANDED TO INCLUDE PREVENTION OF CHRONIC MIGRAINE https://www.neurologylive.com/view/atogepant-indication-expanded-include-prevention-chronic-migraine FDA GRANTS BREAKTHROUGH DEVICE DESIGNATION TO REACH NEURO’S CHRONIC STROKE PLATFORM https://www.neurologylive.com/view/fda-grants-breakthrough-device-designation-reach-neuro-chronic-stroke-platform FDA APPROVES CSL BEHRING'S IMMUNE GLOBULIN SUBCUTANEOUS PREFILLED SYRINGE FOR PI AND CIDP https://www.neurologylive.com/view/fda-approves-csl-behring-immune-globulin-subcutaneous-prefilled-syringe-pi-cidp __ * Thanks for listening to the ® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com http://neurologylive.com/. REFERENCE 1. Zivadinov R, Jakimovski D, Burnham A, et al. Comprehensive Assessment of Severely Affected Multiple Sclerosis (CASA-MS) Study. Presented at: ACTRIMS Forum; February 25-28, 2023; San Diego, CA. P430. www.abstractsonline.com/pp8/#!/10822/presentation/468 http://www.abstractsonline.com/pp8/#!/10822/presentation/468

29m
Apr 21, 2023